Richard Fisher
Technik-/Wissenschafts-/F&E-Leiter bei Proclara Biosciences, Inc.
Aktive Positionen von Richard Fisher
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 | - |
Karriereverlauf von Richard Fisher
Ehemalige bekannte Positionen von Richard Fisher
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GlycoFi, Inc.
GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Technik-/Wissenschafts-/F&E-Leiter | - | 01.01.2006 |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1998 | 01.01.2005 |
CytoMed, Inc.
CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.1994 | 02.01.1998 |
Intranasal Therapeutics, Inc. | Technik-/Wissenschafts-/F&E-Leiter | 01.11.2006 | - |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Corporate Officer/Principal | - | - |
Ausbildung von Richard Fisher
University of Iowa | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 7 |
2 |
Operativ
Chief Tech/Sci/R&D Officer | 6 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Proclara Biosciences, Inc.
Proclara Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Proclara Biosciences, Inc. provides treatment of chronic neurodegenerative diseases. The firm develops therapies for protein misfolding diseases, such as chronic diseases of aging and certain orphan indications by harnessing General Amyloid Interaction Motif (GAIM), which is a multi-target approach that reduces levels of pathological misfolded protein deposits. The company was founded by Hampus Jacob Hillerstrom and Jonathan Eithan Solomon in December 2006 and is headquartered in Cambridge, MA. | Health Technology |
CytoMed, Inc.
CytoMed, Inc. Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., CytoMed, Inc. is a company that develops therapeutics for cancer treatment. The company is based in Cambridge, MA. CytoMed was acquired by LeukoSite, Inc., part of Takeda Pharmaceutical Co., Ltd. from December 22, 1999 on February 12, 1999 for $19.29 million. | Health Technology |
GlycoFi, Inc.
GlycoFi, Inc. BiotechnologyHealth Technology GlycoFi, Inc. develops biopharmaceutical products. It provides protein production technology to develop, produce and commercialize biotherapeutics products. The company was founded by Tillman Gerngross in 2000 and is headquartered in Lebanon, NH. | Health Technology |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Commercial Services |
Intranasal Therapeutics, Inc. |
- Börse
- Insiders
- Richard Fisher
- Erfahrung